基于中膜结构和生理刚度的PCL大孔血管支架的设计制备及其体内移植研究

先天性心脏病外科治疗常需借助人工血管来纠治心脏和血管发育异常，但目前的人工血管存在诸多缺陷，导致患儿预后不佳需要多次更换管道。随着材料学和生物医学的发展，利用组织工程学的方法构建组织相容性好且具有生长活性的人工血管成为了研究的热点。经过多年的发展，构建出具备完整内膜结构的组织工程血管已成可能，但是未能形成有功能的中膜结构，仍然是该领域有待攻克的难题。本项目基于血管中膜平滑肌细胞层在生理结构和功能上的特点，通过对材料的结构和性能进行设计，拟将聚氧化乙烯（PEO）和左旋聚乳酸（PLLA）载入到PCL纤维支架中，制备出既具有平行结构又具有一定刚度的PCL纤维材料，指导中膜平滑肌细胞的定向排列，同时引导中膜平滑肌细胞向收缩型转变，获得正常的生理结构和功能。最后对所构建的人工血管进行自体血管移植并评估其功能。本研究将有助于为患儿提供生物相容性好、富有生长潜能的人工血管，提高我国先天性心脏病手术疗效。

Surgical treatment of congenital heart disease often requires the use of artificial blood vessels to correct the abnormal development of heart and blood vessels, but there are many defects in the current artificial blood vessels, resulting in poor prognosis of children and the need to replace the pipeline many times..With the development of materials science and biomedicine, the construction of artificial blood vessels with good histocompatibility and growth activity by tissue engineering has become a research hotspot..After years of development, it has become possible to construct tissue engineering blood vessels with complete intima structure, but the failure to form functional mesenchymal structure is still a problem to be solved in this field..This project based on membrane in vascular smooth muscle cell layer on the physiological structure and function characteristics, through the study of the design of the structure and properties of materials, the proposed polyethylene oxide (PEO) and levorotatory polylactic acid (PLLA) loaded into PCLS scaffolds, was prepared with parallel structure and has a certain stiffness PCLS fiber material, guiding the directional alignment of smooth muscle cells in the membrane, and guide the membrane in the smooth muscle cells to deflating, obtain normal physiological structure and function..Finally, the constructed artificial blood vessel was transplanted with autologous blood vessel and its function was evaluated..This study will help to provide artificial blood vessels with good biocompatibility and growth potential for children and improve the surgical efficacy of congenital heart disease in China.